Drug Trial Radar · NCT07447986
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Mar 26, 2026
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study. The primary objective was to evaluate the efficacy of SG301 SC injection in participants with Systemic Lupus Erythematosus (SLE) based on the Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response rate. The secondary objectives were to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of SG301 SC injection in these participants .
Conditions
- Systemic Lupus Erythematosus (SLE)
Interventions
SG301 SC InjectionDrug
One injection per week for 8 doses, followed by one injection every two weeks for another 8 doses, with a total of 16 injections administered.
SG301 SC InjectionDrug
One injection per week for 8 doses, followed by one injection every two weeks for another 8 doses, with a total of 16 injections administered, among which 2 injections are placebos
SG301 SC placeboDrug
One injection per week for 8 doses, followed by one injection every two weeks for another 8 doses, with a total of 16 injections administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4)Time frame: From baseline to week 25
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Xiamen Hospital of Traditional Chinese Medicine
Xiamen, Fujian, China · Recruiting
Xiamen University Affiliated Zhongshan Hospital
Xiamen, Fujian, China · Recruiting
GanSu Provincial Hospital
Lanzhou, Gansu, China · Recruiting
The First Hospital of Lanzhou University
Lanzhou, Gansu, China · Recruiting
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Shenzhen People's Hospital
Shenzhen, Guangdong, China · Recruiting
The First Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China · Recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Hebei Zhongyuan Petrolium Central Hospital
Langfang, Hebei, China · Recruiting
Hebei General Hospital
Shijiazhuang, Hebei, China · Recruiting
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Not yet recruiting
Luoyang Central Hospital
Luoyang, Henan, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Recruiting
Pingxiang People's Hospital
Pingxiang, Henan, China · Recruiting
People's Hospital of Zhengzhou
Zhengzhou, Henan, China · Recruiting
JingZhou Central Hospital
Jingzhou, Hubei, China · Recruiting
Shiyan People's Hospital
Shiyan, Hubei, China · Recruiting
The Central Hospital of Wuhan
Wuhan, Hubei, China · Recruiting
Yichang Central People's Hospital
Yichang, Hubei, China · Recruiting
Zhuzhou Central Hospital
Zhuzhou, Hunan, China · Recruiting
Changzhou Second People's Hospital
Changzhou, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China · Recruiting
Yichun People's Hospital
Yichun, Jiangxi, China · Recruiting
Jilin Provincial People's Hospital
Changchun, Jilin, China · Recruiting
Jilin University First Hospital
Changchun, Jilin, China · Recruiting
Dalian Municipal Central Hospital
Dalian, Liaoning, China · Recruiting
Jining First People's Hospital
Jining, Shandong, China · Recruiting
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China · Recruiting
The First Affiliated Hospital of Gannan Medical University
Ganzhou, Shanxi, China · Recruiting
Linfen Central Hospital
Linfen, Shanxi, China · Recruiting
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First People's Hospital of Yunnan Prevince
Kunming, Yunnan, China · Recruiting
Huzhou Third People's Hospital
Huzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.